The efficacy of acute electroconvulsive therapy in atypical depression
- PMID: 18278988
- PMCID: PMC3670137
- DOI: 10.4088/jcp.v69n0310
The efficacy of acute electroconvulsive therapy in atypical depression
Abstract
Objective: This study examined the characteristics and outcomes of patients with major depressive disorder (MDD), with or without atypical features, who were treated with acute bilateral electroconvulsive therapy (ECT).
Method: Analyses were conducted with 489 patients who met DSM-IV criteria for MDD. Subjects were identified as typical or atypical on the basis of the Structured Clinical Interview for DSM-IV obtained at baseline prior to ECT. Depression symptom severity was measured by the 24-item Hamilton Rating Scale for Depression (HAM-D(24)) and the 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR(30)). Remission was defined as at least a 60% decrease from baseline in HAM-D(24) score and a total score of 10 or below on the last 2 consecutive HAM-D(24) ratings. The randomized controlled trial was performed from 1997 to 2004.
Results: The typical (N = 453) and atypical (N = 36) groups differed in several sociodemographic and clinical variables including gender (p = .0071), age (p = .0005), treatment resistance (p = .0014), and age at first illness onset (p < .0001) and onset of current episode (p = .0008). Following an acute course of bilateral ECT, a considerable portion of both the typical (67.1%) and the atypical (80.6%) groups reached remission. The atypical group was 2.6 (95% CI = 1.1 to 6.2) times more likely to remit than the typical group after adjustment for age, psychosis, gender, clinical site, and depression severity based on the HAM-D(24).
Conclusion: Acute ECT is an efficacious treatment for depressed patients with typical or atypical symptom features.
Trial registration: clinicaltrials.gov Identifier: NCT00000375.
Comment in
-
ECT not proven for atypical depression.J Clin Psychiatry. 2008 Oct;69(10):1662; author reply 1662-3. doi: 10.4088/jcp.v69n1017e. J Clin Psychiatry. 2008. PMID: 19192452 No abstract available.
References
-
- Sargant W. The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs. J Neuropsychiatr. 1962;3(suppl 1):S96–S103. - PubMed
-
- Sotsky SM, Simmens SJ. Pharmacotherapy response and diagnostic validity in atypical depression. J Affect Disord. 1999;54:237–247. - PubMed
-
- Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry. 1996;37:375–383. - PubMed
-
- Stewart JW, McGrath PJ, Rabkin JG, et al. Atypical depression: a valid clinical entity? Psychiatr Clin North Am. 1993;16:479–495. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- R10 MH055486/MH/NIMH NIH HHS/United States
- MH55485/MH/NIMH NIH HHS/United States
- U01 MH055495/MH/NIMH NIH HHS/United States
- MH55495/MH/NIMH NIH HHS/United States
- MH55484/MH/NIMH NIH HHS/United States
- R10 MH055484/MH/NIMH NIH HHS/United States
- R01 MH055495/MH/NIMH NIH HHS/United States
- R01 MH055484/MH/NIMH NIH HHS/United States
- R10 MH055495/MH/NIMH NIH HHS/United States
- R01 MH055489/MH/NIMH NIH HHS/United States
- MH55486/MH/NIMH NIH HHS/United States
- R01 MH055486/MH/NIMH NIH HHS/United States
- MH55489/MH/NIMH NIH HHS/United States
- R10 MH055489/MH/NIMH NIH HHS/United States
LinkOut - more resources
Miscellaneous